abstract |
The present invention relates to conditional bispecific oriented activated constructs or COBRAs, administered in the form of an active prodrug. Upon exposure to tumor proteases, these constructs are cleaved and activated so that they bind to both tumor target antigens (TTAs) and CD3 and thus recruit T cells expressing CD3 to the tumor, causing treatment. |